HutchMed (China) (00013.HK): The renewal of the listing of Vosaroxin (Savolitinib) on the Chinese National Medical Insurance Pharmaceutical List was successful under the current terms.
Hutchmed (China) announced on November 28th that following the medical insurance renewal with the China National Medical Insurance Administration ("National Medical Insurance Administration"), Orpathys (selpercatinib) will continue to be included in the new version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List" ("Medical Insurance Drug List") effective from January 1, 2025, maintaining the same terms as the current two-year agreement. Orpathys is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI). It was conditionally approved in China in June 2021.
HUTCHMED (China) To Launch Oral CRC Drug in Japan With Takeda; Shares Slide 3%
Express News | Reported Earlier, HUTCHMED Secures Milestone Payment As Takeda Rolls Out FRUZAQLA In Japanese Market
Hutchmed (China) (00013.HK) announced that FRUQUINTINIB (Fruquintinib) was launched by Takeda in Japan.
On November 22, Hutchmed (China) announced that following the approval of the pricing in Japan, FRUZAQLA (fruquintinib) 1mg/5mg capsules will be commercially launched by its partner Takeda (TSE: 4502 / NYSE: TAK) for the treatment of previously treated metastatic colorectal cancer patients, and Hutchmed (China) will receive a milestone payment. Previously, FRUZAQLA has obtained manufacturing and sales approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan. FRUZAQLA is the first approved treatment for metastatic colorectal cancer in Japan in over a decade.
Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday
Hutchmed (China) (00013.HK) appointed Hu Zhaohong as an independent non-executive director and a member of the technical committee.
Gelonghui, November 20 - Hutchmed (00013.HK) today announced that Hu Chaohong has been appointed as the company's independent non-executive director and member of the technical committee, effective from November 21, 2024. Dr. Hu has over 20 years of experience in therapeutic antibodies, antibody-drug conjugates, and vaccine development. Throughout her career, she has demonstrated strong leadership and innovation capabilities, leading multiple research and development programs. Dr. Hu's expertise spans from early discovery to clinical development and commercialization. She also has a good track record in successful business development and establishing strategic partnerships (including licensing and collaboration).
